

## Cerep reports second quarter 2000 consolidated sales: up 76%

**Rueil-Malmaison, France 9 August 2000** - Cerep (Nouveau Marché: CEREP) today announced second quarter sales for the three-month period ended June 30, 2000.

The drug discovery company reported second quarter sales of FF 26.6 million (€ 4 million) compared to FF 15.1 million (€ 2.3 million) for the same period in 1999, an increase of 76,1%. For the first half, the sales were FF 52.8 million (€ 8 million) compared to FF 30.0 million (€ 4,6 million) for the same period in 1999, an increase of 76%.

Sales increased in both the fee-for-service area and in collaborative efforts. Service revenue for the quarter increased to FF 15.3 million (€ 2.3 million) compared to FF 11.4 million (€ 1.7 million) in the second quarter of 1999, a progression of 34,2%. Collaborative drug research programs sales grew to FF 11.3 million (€ 1.7 million) versus FF 3.8 million (€ 0.6 million) in 1999 an increase of 197,3%. For the first half, service revenues totaled FF 30.6 million (€ 4.7 million) an increase of 36% over comparable 1999 sales of FF 22.5 million (€ 3.4 million) and collaborative drug research program sales grew to FF 22.3 million (€ 3.4 million) a 197,3% increase over 1999 sales of FF 7.5 million (€ 1.1 million).

Thierry Jean, President and CEO, commented : *“ We are pleased by the continued good performance in both fee-for-service and collaborations. Cerep has shown that it can grow current revenues significantly while preparing itself for additional collaboration programs. Our backlog continues to be strong, and we continue to pursue very promising drug discovery collaboration opportunities. ”*

### About Cerep

*Cerep's mission is to optimize the drug discovery process. Cerep provides solutions to the pharmaceutical industry for faster and cost effective drug discovery by identifying at early stages compounds that will fail in development. Cerep integrated platform encompasses a whole range of technologies including chemistry, biology, and informatics. The company was introduced on the Nouveau Marché on 18 February 1998 (Sicovam code: 6179).*

*Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the prospectus relating to the company's recent public offering.*